HEMO — Hemogenyx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Strategic Investment from Prevail Partners, LLC
Half-year Report
CDX Development Update
Macrophage-Directed Therapies Summit Presentation
Operations Update
Posting of Annual Report & Notice of AGM
Final Results
Placing to Raise US$4.2 million
CBR Brain Delivery
FDA Consents to Phase I Trials of HEMO-CAR-T
Brief: Hemogenyx Pharma Reports Approval And Issuance Of U.S. Conditioning Patent
Submission of Complete Response to Clinical Hold
Brief: Hemogenyx Pharma Announces Successful Completion Of Process Qualification Run Of End-To-End Process For Manufacture Of HEMO-CAR-T Cells
Placing to Raise £534,375
Brief: Hemogenyx Pharmaceuticals Announces Successful Completion Of Re-Manufacturing Of An Improved Lentivirus Devoid Of Splice Variants
Half-year Report
UK's Hemogenyx Pharma rises on investment from Prevail Partners
Brief: Hemogenyx Pharma Receives Investment From Prevail Partners
Brief: Hemogenyx Pharma Says Clinical Hold Lift Plan Accepted By FDA